Drug Profile

Erythropoietin (Y-shaped pegylation) - Xiamen Amoytop Biotech/BioGeneric Pharma

Alternative Names: YPEG-EPO; YPEG-rhEPO

Latest Information Update: 26 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xiamen Amoytop Biotech
Class Antianaemics; Erythropoietins
Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Anaemia

Most Recent Events

05 Jan 2022 Xiamen Amoytop Biotech completes a phase II trial in Anaemia (In adults, In the elderly) in China (SC, Injection) (NCT04885647)
12 Nov 2020 Phase-II clinical trials in Anaemia (In adults, In the elderly) in China (SC, Injection) (NCT04885647)
30 Sep 2012 Phase-I clinical trials in Anaemia (In volunteers) in China (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com